{"id":420876,"date":"2025-09-23T00:00:00","date_gmt":"2025-09-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0011-2025-biopharma-heart-failure-current-treatment-treatment-algorithms-claims-data-analysis-heart-failure-with\/"},"modified":"2026-03-31T10:25:03","modified_gmt":"2026-03-31T10:25:03","slug":"algocv0011-2025-biopharma-heart-failure-current-treatment-treatment-algorithms-claims-data-analysis-heart-failure-with","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0011-2025-biopharma-heart-failure-current-treatment-treatment-algorithms-claims-data-analysis-heart-failure-with\/","title":{"rendered":"Heart Failure &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Heart Failure with Reduced Ejection Fraction (US)"},"content":{"rendered":"<p>Drug treatment of heart failure with reduced ejection fraction (<abbr data-abbreviation-entity=\"6461\" title=\"heart failure with reduced ejection fraction\">HFrEF<\/abbr>) is well established, backed by a wealth of supporting evidence from clinical trials. <abbr data-abbreviation-entity=\"5703\" title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors and beta blockers are the first-line treatment, usually in combination with diuretics when fluid overload is present. The addition of a second- or third-line treatment is often needed to better manage the disease. Given the heavily genericized nature of the market, branded agents have had difficulty establishing a foothold. However, the use of Entresto (sacubitril \/ valsartan) and <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors has grown steadily since their launch. This report provides important insight into how these agents are used in the management of <abbr data-abbreviation-entity=\"6461\" title=\"heart failure with reduced ejection fraction\">HFrEF<\/abbr> and how practices are evolving.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr data-abbreviation-entity=\"6461\" title=\"heart failure with reduced ejection fraction\">HFrEF<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr data-abbreviation-entity=\"6461\" title=\"heart failure with reduced ejection fraction\">HFrEF<\/abbr> patients?<\/li>\n<li>How have <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"6461\" title=\"heart failure with reduced ejection fraction\">HFrEF<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"6461\" title=\"heart failure with reduced ejection fraction\">HFrEF<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<div>\n<div>\n<div>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW152425059 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<p><strong>Key companies: <\/strong>Pfizer, Merck &#038; Co., Novartis, <abbr title=\"GlaxoSmithKline\">GSK<\/abbr>, AstraZeneca, Johnson &#038; Johnson Innovative Medicine, Eli Lilly, Boehringer Ingelheim, Amgen<\/p>\n<p><strong>Key drugs:<\/strong> <abbr data-abbreviation-entity=\"5680\" title=\"angiotensin-converting enzyme\">ACE<\/abbr> inhibitors, <abbr title=\"angiotensin II receptor blocker\">ARB<\/abbr>s, beta blockers, <abbr data-abbreviation-entity=\"7152\" title=\"mineralocorticoid receptor antagonist\">MRA<\/abbr>s, diuretics, <abbr data-abbreviation-entity=\"5686\" title=\"calcium channel blocker\">CCB<\/abbr>s, nitrates, ivabradine, vericiguat, Entresto (sacubitril \/ valsartan), <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors<\/p>\n<p><strong>Key feature: <\/strong>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-420876","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-heart-failure","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420876\/revisions"}],"predecessor-version":[{"id":575735,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420876\/revisions\/575735"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=420876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}